{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T10:49:02Z","timestamp":1791629342679,"version":"4.3.4"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["50461-2025"],"award-info":[{"award-number":["50461-2025"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cancer has been the leading cause of death and imposing tremendous socioeconomical pressure worldwide. It is considered the most difficult disease to tackle and major obstacle for extending life expectancy. Radiopharmaceuticals in the field of cancer diagnosis and therapy have drawn a lot of research interest past years due to clinical success, e.g. [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu-PSMA-617 (Pluvicto\u00ae) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Antibody-based radiopharmaceuticals are the most studied in the field of nuclear medicine for cancer attributed to antibody\u2019s great tumor targeting ability. In this manuscript, recent preclinical studies of developing imaging and therapeutic radiopharmaceuticals based on antibody or antibody fragments, including affibody and nanobody, are introduced.\n                  <\/jats:p>","DOI":"10.1007\/s13139-025-00969-3","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T02:56:00Z","timestamp":1764644160000},"page":"166-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of Antibody and Antibody Fragment-Based Radiopharmaceuticals for Cancer Imaging and Therapy"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7081-884X","authenticated-orcid":false,"given":"Chi Soo","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"969_CR1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2967\/jnumed.117.193888","volume":"59","author":"JE Mortimer","year":"2018","unstructured":"Mortimer JE, Bading JR, Park JM, Frankel PH, Carroll MI, Tran TT, et al. Tumor uptake of (64)Cu-DOTA-Trastuzumab in patients with metastatic breast cancer. J Nucl Med. 2018;59:38\u201343.","journal-title":"J Nucl Med"},{"key":"969_CR2","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1021\/mp500323d","volume":"11","author":"BV Marquez","year":"2014","unstructured":"Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, et al. Evaluation of (89)Zr-pertuzumab in breast cancer xenografts. Mol Pharm. 2014;11:3988\u201395.","journal-title":"Mol Pharm"},{"key":"969_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1007\/s10120-019-01035-6","volume":"23","author":"X Guo","year":"2020","unstructured":"Guo X, Zhou N, Chen Z, Liu T, Xu X, Lei X, et al. Construction of (124)I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. Gastric Cancer. 2020;23:614\u201326.","journal-title":"Gastric Cancer"},{"key":"969_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2967\/jnumed.115.162024","volume":"57","author":"M Keyaerts","year":"2016","unstructured":"Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27\u201333.","journal-title":"J Nucl Med"},{"key":"969_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s11307-015-0912-y","volume":"18","author":"AC Lockhart","year":"2016","unstructured":"Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J. Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors. Mol Imaging Biol. 2016;18:446\u201353.","journal-title":"Mol Imaging Biol"},{"key":"969_CR6","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1158\/1078-0432.CCR-17-0311","volume":"23","author":"F Bensch","year":"2017","unstructured":"Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, et al. (89)Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. Clin Cancer Res. 2017;23:6128\u201337.","journal-title":"Clin Cancer Res"},{"key":"969_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.nucmedbio.2019.01.007","volume":"70","author":"Y Tang","year":"2019","unstructured":"Tang Y, Hu Y, Liu W, Chen L, Zhao Y, Ma H, et al. A radiopharmaceutical [(89)Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo. Nucl Med Biol. 2019;70:23\u201331.","journal-title":"Nucl Med Biol"},{"key":"969_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23531-z","volume":"12","author":"LD Stone","year":"2022","unstructured":"Stone LD, Massicano AVF, Stevens TM, Warram JM, Morlandt AB, Lapi SE, et al. (89)Zr-panitumumab PET imaging for preoperative assessment of ameloblastoma in a PDX model. Sci Rep. 2022;12:19187.","journal-title":"Sci Rep"},{"key":"969_CR9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2016.11.020","volume":"122","author":"J van Loon","year":"2017","unstructured":"van Loon J, Even AJG, Aerts H, Ollers M, Hoebers F, van Elmpt W, et al. PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. Radiother Oncol. 2017;122:267\u201373.","journal-title":"Radiother Oncol"},{"key":"969_CR10","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24:1852\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"969_CR11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.7150\/thno.87243","volume":"14","author":"H He","year":"2024","unstructured":"He H, Qi X, Fu H, Xu J, Zheng Q, Chen L. Imaging diagnosis and efficacy monitoring by [89Zr]Zr-DFO-KN035 immunoPET in patients with PD-L1-positive solid malignancies. Theranostics. 2024;14(1):392\u2013405.","journal-title":"Theranostics"},{"key":"969_CR12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.annonc.2021.10.213","volume":"33","author":"IC Kok","year":"2022","unstructured":"Kok IC, Hooiveld JS, van de Donk PP, Giesen D, van der Veen EL, Lub-de Hooge MN, et al. (89)Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. Ann Oncol. 2022;33:80\u20138.","journal-title":"Ann Oncol"},{"key":"969_CR13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.119.229781","volume":"61","author":"N Pandit-Taskar","year":"2020","unstructured":"Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O\u2019Donoghue JA, et al. First-in-humans imaging with (89)Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting. J Nucl Med. 2020;61:512\u20139.","journal-title":"J Nucl Med"},{"key":"969_CR14","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM, et al. [89Zr]Zr-girentuximab for PET\u2013CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25:1277\u201387.","journal-title":"Lancet Oncol"},{"key":"969_CR15","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00259-014-2830-7","volume":"41","author":"N Pandit-Taskar","year":"2014","unstructured":"Pandit-Taskar N, O\u2019Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. (8)(9)Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:2093\u2013105.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR16","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2967\/jnumed.116.176206","volume":"57","author":"N Pandit-Taskar","year":"2016","unstructured":"Pandit-Taskar N, O\u2019Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J Nucl Med. 2016;57:1858\u201364.","journal-title":"J Nucl Med"},{"issue":"2","key":"969_CR17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1039\/D0MD00319K","volume":"12","author":"M Guleria","year":"2021","unstructured":"Guleria M, Sharma R, Amirdhanayagam J, Sarma HD, Rangarajan V, Dash A, et al. Formulation and clinical translation of [(177)Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer. RSC Med Chem. 2021;12(2):263\u201377.","journal-title":"RSC Med Chem"},{"key":"969_CR18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/COC.0000000000000353","volume":"41","author":"RF Meredith","year":"2018","unstructured":"Meredith RF, Torgue JJ, Rozgaja TA, Banaga EP, Bunch PW, Alvarez RD, et al. Safety and Outcome Measures of First-in-Human Intraperitoneal alpha Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol. 2018;41:716\u201321.","journal-title":"Am J Clin Oncol"},{"key":"969_CR19","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S2352-3026(15)00020-4","volume":"2","author":"P Chevallier","year":"2015","unstructured":"Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015;2:e108\u201317.","journal-title":"Lancet Haematol"},{"issue":"1","key":"969_CR20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2967\/jnumed.109.066597","volume":"51","author":"S Shen","year":"2010","unstructured":"Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, et al. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med. 2010;51(1):150\u20137.","journal-title":"J Nucl Med"},{"key":"969_CR21","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","volume":"28","author":"TL Rosenblat","year":"2022","unstructured":"Rosenblat TL, McDevitt MR, Carrasquillo JA, Pandit-Taskar N, Frattini MG, Maslak PG, et al. Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator Actinium-225-Lintuzumab. Clin Cancer Res. 2022;28:2030\u20137.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"969_CR22","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1182\/bloodadvances.2020002583","volume":"4","author":"A Kolstad","year":"2020","unstructured":"Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, et al. Phase 1\/2a study of 177Lu-lilotomab satetraxetan in relapsed\/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091\u2013101.","journal-title":"Blood Adv"},{"key":"969_CR23","first-page":"12","volume":"9","author":"PKE B\u00f6rjesson","year":"2003","unstructured":"B\u00f6rjesson PKE, Postema EJ, Roos JC, Colnot DR, Marres HAM, van Schie MH, et al. Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2003;9:12.","journal-title":"Clin Cancer Res"},{"key":"969_CR24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.eururo.2015.11.033","volume":"69","author":"CH Muselaers","year":"2016","unstructured":"Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, et al. Phase 2 study of lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2016;69:767\u201370.","journal-title":"Eur Urol"},{"key":"969_CR25","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1200\/JCO.2007.11.1807","volume":"25","author":"K Kramer","year":"2007","unstructured":"Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25:5465\u201370.","journal-title":"J Clin Oncol"},{"key":"969_CR26","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182\u201391.","journal-title":"Clin Cancer Res"},{"key":"969_CR27","first-page":"9","volume":"9","author":"AM Scott","year":"2003","unstructured":"Scott AM, Wiseman G, Welt S, Adjei A, Lee F-T, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:9.","journal-title":"Clin Cancer Res"},{"key":"969_CR28","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","volume":"23","author":"T Liersch","year":"2005","unstructured":"Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005;23:6763\u201370.","journal-title":"J Clin Oncol"},{"key":"969_CR29","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","volume":"120","author":"W Wei","year":"2020","unstructured":"Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787\u2013851.","journal-title":"Chem Rev"},{"key":"969_CR30","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1007\/s00259-025-07205-2","volume":"52","author":"K Zeven","year":"2025","unstructured":"Zeven K, Dierick H, Sevenois M, Baudhuin H, Navarro L, Van den Block S, et al. Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers. Eur J Nucl Med Mol Imaging. 2025;52:3833\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119154","volume":"24","author":"OO Krasnovskaya","year":"2023","unstructured":"Krasnovskaya OO, Abramchuck D, Erofeev A, Gorelkin P, Kuznetsov A, Shemukhin A, et al. Recent advances in (64)Cu\/(67)Cu-based radiopharmaceuticals. Int J Mol Sci. 2023;24:9154.","journal-title":"Int J Mol Sci"},{"key":"969_CR32","first-page":"10","volume":"42","author":"M Shokeen","year":"2008","unstructured":"Shokeen M, Anderson CJ. Molecular imaging of cancer with Copper-64 radiopharmaceuticals and positron emissiontomography (PET). Acc Chem Res. 2008;42:10.","journal-title":"Acc Chem Res"},{"key":"969_CR33","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.7150\/thno.56736","volume":"12","author":"J Schmitt","year":"2022","unstructured":"Schmitt J, Schwenck J, Maurer A, Przybille M, Sonanini D, Reischl G, et al. Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma. Theranostics. 2022;12:5615\u201330.","journal-title":"Theranostics"},{"key":"969_CR34","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00259-024-07022-z","volume":"52","author":"X Yang","year":"2025","unstructured":"Yang X, Liu J, Li C, Zheng L, Lu X, Zhou Z, et al. Preclinical evaluation of 64Cu\/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma. Eur J Nucl Med Mol Imaging. 2025;52:1751\u201363.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR35","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00018-014-1763-4","volume":"72","author":"D Samanta","year":"2015","unstructured":"Samanta D, Almo SC. Nectin family of cell-adhesion molecules: structural and molecular aspects of function and specificity. Cell Mol Life Sci. 2015;72:645\u201358.","journal-title":"Cell Mol Life Sci"},{"key":"969_CR36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2016.02.049","volume":"375","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang Z, et al. A novel PI3K\/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett. 2016;375:179\u201389.","journal-title":"Cancer Lett"},{"key":"969_CR37","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00280-015-2794-8","volume":"76","author":"D Das","year":"2015","unstructured":"Das D, Satapathy SR, Siddharth S, Nayak A, Kundu CN. Nectin-4 increased the 5-FU resistance in colon cancer cells by inducing the PI3K-AKT cascade. Cancer Chemother Pharmacol. 2015;76:471\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"969_CR38","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1021\/acs.molpharmaceut.5c00469","volume":"22","author":"W Huang","year":"2025","unstructured":"Huang W, Li L, Liang Y, Yang Q, Mixdorf JC, Engle JW, et al. ImmunoPET imaging of Nectin4 expression in gastric and bladder cancer using [(64)Cu]Cu-NOTA-Padcev. Mol Pharm. 2025;22:3468\u201378.","journal-title":"Mol Pharm"},{"key":"969_CR39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235936","volume":"13","author":"JA Delage","year":"2021","unstructured":"Delage JA, Gnesin S, Prior JO, Barbet J, Le Saec P, Marionneau-Lambot S, et al. Copper-64-labeled 1C1m-Fc, a new tool for TEM-1 PET imaging and prediction of Lutetium-177-labeled 1C1m-Fc therapy efficacy and safety. Cancers (Basel). 2021;13:5936.","journal-title":"Cancers (Basel)"},{"key":"969_CR40","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1021\/acs.bioconjchem.0c00541","volume":"31","author":"T Uehara","year":"2020","unstructured":"Uehara T, Kanazawa N, Suzuki C, Mizuno Y, Suzuki H, Hanaoka H, et al. Renal handling of (99m)Tc-labeled antibody Fab fragments with a linkage cleavable by enzymes on brush border membrane. Bioconjug Chem. 2020;31:2618\u201327.","journal-title":"Bioconjug Chem"},{"key":"969_CR41","doi-asserted-by":"crossref","first-page":"21556","DOI":"10.1021\/acsomega.1c02516","volume":"6","author":"H Suzuki","year":"2021","unstructured":"Suzuki H, Kise S, Kaizuka Y, Watanabe R, Sugawa T, Furukawa T. Copper-64-labeled antibody fragments for immuno-PET\/radioimmunotherapy with low renal radioactivity levels and amplified tumor-kidney ratios. ACS Omega. 2021;6:21556\u201362.","journal-title":"ACS Omega"},{"key":"969_CR42","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23:4290\u2013300.","journal-title":"Clin Cancer Res"},{"key":"969_CR43","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207\u201319.","journal-title":"N Engl J Med"},{"key":"969_CR44","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","volume":"45","author":"L Kang","year":"2018","unstructured":"Kang L, Jiang D, England CG, Barnhart TE, Yu B, Rosenkrans ZT, et al. Immunopet imaging of CD38 in murine lymphoma models using (89)Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018;45:1372\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR45","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s00259-021-05593-9","volume":"49","author":"L Kang","year":"2022","unstructured":"Kang L, Li C, Yang Q, Sutherlin L, Wang L, Chen Z, et al. (64)Cu-labeled daratumumab F(ab\u2019)(2) fragment enables early visualization of CD38-positive lymphoma. Eur J Nucl Med Mol Imaging. 2022;49:1470\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","volume":"72","author":"F Borri","year":"2021","unstructured":"Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136\u201345.","journal-title":"Semin Cancer Biol"},{"key":"969_CR47","volume":"10","author":"Y Wen","year":"2022","unstructured":"Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, et al. A literature review of the promising future of TROP2: a potential drug therapy target. Ann Transl Med. 2022;10:1403.","journal-title":"Ann Transl Med"},{"key":"969_CR48","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1007\/s00259-025-07167-5","volume":"52","author":"W Huang","year":"2025","unstructured":"Huang W, Zhang Y, Xiao X, Yang Q, Mixdorf JC, Sun X, et al. ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [(64)Cu]Cu-NOTA-Trodelvy-F(ab\u2019)(2). Eur J Nucl Med Mol Imaging. 2025;52:3223\u201337.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nucmedbio.2012.08.004","volume":"40","author":"MA Deri","year":"2013","unstructured":"Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET imaging with (8)(9)Zr: from radiochemistry to the clinic. Nucl Med Biol. 2013;40:3\u201314.","journal-title":"Nucl Med Biol"},{"key":"969_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10967-017-5358-z","volume":"314","author":"AR Jalilian","year":"2017","unstructured":"Jalilian AR, Osso JA. Production, applications and status of zirconium-89 immunoPET agents. J Radioanal Nucl Chem. 2017;314:7\u201321.","journal-title":"J Radioanal Nucl Chem"},{"key":"969_CR51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijom.2006.11.003","volume":"36","author":"J Hong","year":"2007","unstructured":"Hong J, Yun PY, Chung IH, Myoung H, Suh JD, Seo BM, et al. Long-term follow up on recurrence of 305 ameloblastoma cases. Int J Oral Maxillofac Surg. 2007;36:283\u20138.","journal-title":"Int J Oral Maxillofac Surg"},{"key":"969_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s40496-016-0085-z","volume":"3","author":"HM Amm","year":"2016","unstructured":"Amm HM, MacDougall M. Molecular signaling in benign odontogenic neoplasia pathogenesis. Curr Oral Health Rep. 2016;3:82\u201392.","journal-title":"Curr Oral Health Rep"},{"key":"969_CR53","volume":"39","author":"M Vered","year":"2003","unstructured":"Vered M, Shohat I, Buchner A. Epidermal growth factor receptor expression in ameloblastoma. Oral Oncol. 2003;39:6.","journal-title":"Oral Oncol"},{"key":"969_CR54","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/ddg.15053_g","volume":"21","author":"S Ugurel","year":"2023","unstructured":"Ugurel S, Gutzmer R. Melanom. J Dtsch Dermatol Ges. 2023;21:343\u20137.","journal-title":"J Dtsch Dermatol Ges"},{"key":"969_CR55","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jaad.2019.01.081","volume":"81","author":"CC Darmawan","year":"2019","unstructured":"Darmawan CC, Jo G, Montenegro SE, Kwak Y, Cheol L, Cho KH, et al. Early detection of acral melanoma: a review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019;81:805\u201312.","journal-title":"J Am Acad Dermatol"},{"key":"969_CR56","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jaad.2022.08.067","volume":"88","author":"MA El Sharouni","year":"2023","unstructured":"El Sharouni MA, Rawson RV, Potter AJ, Paver EC, Wilmott JS, Witkamp AJ, et al. Melanomas in children and adolescents: clinicopathologic features and survival outcomes. J Am Acad Dermatol. 2023;88:609\u201316.","journal-title":"J Am Acad Dermatol"},{"key":"969_CR57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ijc.29370","volume":"137","author":"N Jouve","year":"2015","unstructured":"Jouve N, Bachelier R, Despoix N, Blin MG, Matinzadeh MK, Poitevin S, et al. CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation. Int J Cancer. 2015;137:50\u201360.","journal-title":"Int J Cancer"},{"key":"969_CR58","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1021\/acs.molpharmaceut.4c00348","volume":"21","author":"X Guo","year":"2024","unstructured":"Guo X, Hu M, Zhang Q, Liu J, Shi J, Tang Y, et al. Preclinical immunoPET imaging using a Zr-89-labeled anti-CD146 monoclonal antibody for diagnosis of melanoma. Mol Pharm. 2024;21:4490\u20137.","journal-title":"Mol Pharm"},{"key":"969_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/83165","volume":"2","author":"AI Chapoval","year":"2001","unstructured":"Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7\u2013H3: a costimulatory molecule for T cell activation and IFN-\u03b3 production. Nat Immunol. 2001;2:5.","journal-title":"Nat Immunol"},{"key":"969_CR60","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00280-017-3508-1","volume":"81","author":"G Li","year":"2018","unstructured":"Li G, Quan Y, Che F, Wang L. B7\u2013H3 in tumors: friend or foe for tumor immunity? Cancer Chemother Pharmacol. 2018;81:245\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"key":"969_CR61","doi-asserted-by":"crossref","first-page":"21785","DOI":"10.1002\/jcp.28936","volume":"234","author":"X Zhou","year":"2019","unstructured":"Zhou X, Ouyang S, Li J, Huang X, Ai X, Zeng Y, et al. The novel non-immunological role and underlying mechanisms of B7\u2013H3 in tumorigenesis. J Cell Physiol. 2019;234:21785\u201395.","journal-title":"J Cell Physiol"},{"key":"969_CR62","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1021\/acs.molpharmaceut.4c00597","volume":"21","author":"M Zheng","year":"2024","unstructured":"Zheng M, Liu Q, Zhang H, Wang Y, Zhang K, Mu H, et al. Development of a specifically labeled (89)Zr antibody for the noninvasive imaging of tumors overexpressing B7\u2013H3. Mol Pharm. 2024;21:5205\u201316.","journal-title":"Mol Pharm"},{"key":"969_CR63","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"969_CR64","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464\u201377.","journal-title":"JAMA"},{"key":"969_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13:125.","journal-title":"J Hematol Oncol"},{"key":"969_CR66","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u2013700.","journal-title":"Blood"},{"key":"969_CR67","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00259-024-06907-3","volume":"52","author":"J Ma","year":"2025","unstructured":"Ma J, Zhang S, Yang N, Shang J, Gao X, Chen J, et al. Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: applications in PET imaging of multiple myeloma. Eur J Nucl Med Mol Imaging. 2025;52:599\u2013610.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR68","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T, et al. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Front Immunol. 2023;14:1332489.","journal-title":"Front Immunol"},{"key":"969_CR69","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12282-024-01565-7","volume":"31","author":"A De Moura","year":"2024","unstructured":"De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024;31:572\u201380.","journal-title":"Breast Cancer"},{"key":"969_CR70","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s00259-025-07106-4","volume":"52","author":"W Huang","year":"2025","unstructured":"Huang W, Li L, Zhou Y, Yang Q, Mixdorf JC, Barnhart TE, et al. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2025;52:2369\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR71","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/acschembio.6b00990","volume":"12","author":"S Miersch","year":"2017","unstructured":"Miersch S, Maruthachalam BV, Geyer CR, Sidhu SS. Structure-directed and tailored diversity synthetic antibody libraries yield novel anti-EGFR antagonists. ACS Chem Biol. 2017;12:1381\u20139.","journal-title":"ACS Chem Biol"},{"key":"969_CR72","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anndiagpath.2010.05.005","volume":"14","author":"HA Alshenawy","year":"2010","unstructured":"Alshenawy HA. Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths. Ann Diagn Pathol. 2010;14:387\u201395.","journal-title":"Ann Diagn Pathol"},{"key":"969_CR73","volume":"18","author":"IS Kim","year":"2017","unstructured":"Kim IS, Koppula S, Park SY, Choi DK. Analysis of epidermal growth factor receptor related gene expression changes in a cellular and animal model of Parkinson\u2019s disease. Int J Mol Sci. 2017;18:430.","journal-title":"Int J Mol Sci"},{"key":"969_CR74","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00280-011-1791-9","volume":"69","author":"JN Jakobsen","year":"2012","unstructured":"Jakobsen JN, Sorensen JB. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;69:289\u201399.","journal-title":"Cancer Chemother Pharmacol"},{"key":"969_CR75","volume":"12","author":"AJ Chang","year":"2013","unstructured":"Chang AJ, De Silva RA, Lapi SE. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Mol Imaging. 2013;12:11.","journal-title":"Mol Imaging"},{"key":"969_CR76","first-page":"10","volume":"6","author":"CWMH Oordt","year":"2015","unstructured":"Oordt CWMH, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget. 2015;6:10.","journal-title":"Oncotarget"},{"key":"969_CR77","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030560","volume":"13","author":"E Alizadeh","year":"2021","unstructured":"Alizadeh E, Behlol Ayaz Ahmed K, Raja Solomon V, Gaja V, Bernhard W, Makhlouf A, et al. (89)Zr-labeled domain II-specific scFv-Fc immunoPET probe for imaging epidermal growth factor receptor in vivo. Cancers (Basel). 2021;13:560.","journal-title":"Cancers (Basel)"},{"key":"969_CR78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000055396","volume":"61","author":"Y Yarden","year":"2001","unstructured":"Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61:13.","journal-title":"Oncology"},{"key":"969_CR79","volume":"135","author":"C Gutierrez","year":"2011","unstructured":"Gutierrez C, Schiff R. HER2 biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135:8.","journal-title":"Arch Pathol Lab Med"},{"key":"969_CR80","doi-asserted-by":"crossref","DOI":"10.1097\/PAP.0000000000000015","volume":"21","author":"U Krishnamurti","year":"2014","unstructured":"Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21:8.","journal-title":"Adv Anat Pathol"},{"issue":"7","key":"969_CR81","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","volume":"21","author":"S Steeland","year":"2016","unstructured":"Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21(7):1076\u2013113.","journal-title":"Drug Discov Today"},{"key":"969_CR82","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1021\/acs.molpharmaceut.3c00360","volume":"20","author":"M Ducharme","year":"2023","unstructured":"Ducharme M, Hall L, Eckenroad W, Cingoranelli SJ, Houson HA, Jaskowski L, et al. Evaluation of [(89)Zr]Zr-DFO-2Rs15d nanobody for imaging of HER2-positive breast cancer. Mol Pharm. 2023;20:4629\u201339.","journal-title":"Mol Pharm"},{"key":"969_CR83","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40336-016-0186-7","volume":"4","author":"S Mahajan","year":"2016","unstructured":"Mahajan S, Divgi CR. The role of iodine-124 positron emission tomography in molecular imaging. Clin Transl Imaging. 2016;4:297\u2013306.","journal-title":"Clin Transl Imaging"},{"key":"969_CR84","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/cancers11111803","volume":"11","author":"A Landras","year":"2019","unstructured":"Landras A, Reger de Moura C, Jouenne F, Lebbe C, Menashi S, Mourah S. CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker. Cancers (Basel). 2019;11:1803.","journal-title":"Cancers (Basel)"},{"key":"969_CR85","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2559.2009.03280.x","volume":"54","author":"Y Li","year":"2009","unstructured":"Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology. 2009;54:677\u201387.","journal-title":"Histopathology"},{"issue":"2","key":"969_CR86","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41401-023-01162-y","volume":"45","author":"XK Ma","year":"2024","unstructured":"Ma XK, Liu TL, Ren YN, Ma XP, Yao Y, Hou XG, et al. 124I-labeled anti-CD147 antibody for noninvasive detection of CD147-positive pan-cancers: construction and preclinical studies. Acta Pharmacol Sin. 2024;45(2):436\u201348.","journal-title":"Acta Pharmacol Sin"},{"key":"969_CR87","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.it.2019.03.005","volume":"40","author":"T Wartewig","year":"2019","unstructured":"Wartewig T, Ruland J. PD-1 tumor suppressor signaling in T cell lymphomas. Trends Immunol. 2019;40:403\u201314.","journal-title":"Trends Immunol"},{"key":"969_CR88","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","volume":"19","author":"H Yamaguchi","year":"2022","unstructured":"Yamaguchi H, Hsu JM, Yang WH, Hung MC. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022;19:287\u2013305.","journal-title":"Nat Rev Clin Oncol"},{"key":"969_CR89","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"969_CR90","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","volume":"37","author":"RW Naumann","year":"2019","unstructured":"Naumann RW, Hollebecque A, Meyer T, Devlin MJ, Oaknin A, Kerger J, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial. J Clin Oncol. 2019;37:2825\u201334.","journal-title":"J Clin Oncol"},{"key":"969_CR91","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1245\/s10434-015-4903-7","volume":"23","author":"SJ Shin","year":"2016","unstructured":"Shin SJ, Jeon YK, Kim PJ, Cho YM, Koh J, Chung DH, et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann Surg Oncol. 2016;23:694\u2013702.","journal-title":"Ann Surg Oncol"},{"key":"969_CR92","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00259-024-06886-5","volume":"52","author":"Y Yao","year":"2024","unstructured":"Yao Y, Ren Y, Hou X, Wang P, Zhu J, Liu S, et al. Construction and preclinical evaluation of a (124)I-labelled bispecific antibody targeting PD-L1 and PD-L2. Eur J Nucl Med Mol Imaging. 2024;52:36\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR93","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","volume":"64","author":"L Emmett","year":"2017","unstructured":"Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64:52\u201360.","journal-title":"J Med Radiat Sci"},{"key":"969_CR94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.semnuclmed.2019.07.006","volume":"50","author":"SJ Goldsmith","year":"2020","unstructured":"Goldsmith SJ. Targeted radionuclide therapy: a historical and personal review. Semin Nucl Med. 2020;50:87\u201397.","journal-title":"Semin Nucl Med"},{"key":"969_CR95","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"969_CR96","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010167","volume":"9","author":"I Saltarella","year":"2020","unstructured":"Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. Cells. 2020;9:167.","journal-title":"Cells"},{"key":"969_CR97","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1158\/0008-5472.CAN-13-1589","volume":"74","author":"DJ Green","year":"2014","unstructured":"Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, et al. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res. 2014;74:1179\u201389.","journal-title":"Cancer Res"},{"key":"969_CR98","volume":"8","author":"L Kang","year":"2021","unstructured":"Kang L, Li C, Rosenkrans ZT, Huo N, Chen Z, Ehlerding EB. CD38\u2010Targeted Theranostics of Lymphoma with 89Zr\/177Lu\u2010Labeled Daratumumab. Adv Sci. 2021;8:2001879.","journal-title":"Adv Sci"},{"key":"969_CR99","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3802\/jgo.2013.24.4.342","volume":"24","author":"YC Chiang","year":"2013","unstructured":"Chiang YC, Chen CA, Chiang CJ, Hsu TH, Lin MC, You SL, et al. Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan. J Gynecol Oncol. 2013;24:342\u201351.","journal-title":"J Gynecol Oncol"},{"key":"969_CR100","doi-asserted-by":"crossref","unstructured":"Peng C, Peng J, Jiang L, You Q, Zheng J, Nin X (n.d.) YKL-40 Protein Levels and Clinical Outcome of Human Endometrial Cancer. J Int Med Res 38:10","DOI":"10.1177\/147323001003800427"},{"key":"969_CR101","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-10-0868","volume":"10","author":"M Faibish","year":"2011","unstructured":"Faibish M, Francescone R, Bentley B, Yan W, Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011;10:742\u201351.","journal-title":"Mol Cancer Ther"},{"key":"969_CR102","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113668","volume":"155","author":"MC Chang","year":"2022","unstructured":"Chang MC, Chiang PF, Kuo YJ, Peng CL, Chen IC, Huang CY, et al. Develop companion radiopharmaceutical YKL40 antibodies as potential theranostic agents for epithelial ovarian cancer. Biomed Pharmacother. 2022;155:113668.","journal-title":"Biomed Pharmacother"},{"key":"969_CR103","volume":"13","author":"A Jacob","year":"2021","unstructured":"Jacob A, Raj R, Allison DB, Myint ZW. Androgen receptor signaling in prostate cancer and therapeutic strategies. Cancers (Basel). 2021;13:5417.","journal-title":"Cancers (Basel)"},{"key":"969_CR104","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78\u201383.","journal-title":"Science"},{"key":"969_CR105","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.celrep.2016.06.081","volume":"16","author":"MD Borromeo","year":"2016","unstructured":"Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 2016;16:1259\u201372.","journal-title":"Cell Rep"},{"key":"969_CR106","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav0891","volume":"11","author":"L Puca","year":"2019","unstructured":"Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci Transl Med. 2019;11:eaav0891.","journal-title":"Sci Transl Med"},{"key":"969_CR107","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","volume":"7","author":"LR Saunders","year":"2015","unstructured":"Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.","journal-title":"Sci Transl Med"},{"key":"969_CR108","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","volume":"16","author":"ML Johnson","year":"2021","unstructured":"Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. J Thorac Oncol. 2021;16:1570\u201381.","journal-title":"J Thorac Oncol"},{"key":"969_CR109","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2203820119","volume":"119","author":"JA Korsen","year":"2022","unstructured":"Korsen JA, Gutierrez JA, Tully KM, Carter LM, Samuels ZV, Khitrov S, et al. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer. Proc Natl Acad Sci USA. 2022;119:e2203820119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"969_CR110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.clim.2016.08.011","volume":"172","author":"M Engelhard","year":"2016","unstructured":"Engelhard M. Anti-CD20 antibody treatment of non-Hodgkin lymphomas. Clin Immunol. 2016;172:101\u20134.","journal-title":"Clin Immunol"},{"key":"969_CR111","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5:22\u201333.","journal-title":"MAbs"},{"key":"969_CR112","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2967\/jnumed.117.203299","volume":"59","author":"JT Yoon","year":"2018","unstructured":"Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL. Evaluation of next-generation anti-CD20 antibodies labeled with (89)Zr in human lymphoma xenografts. J Nucl Med. 2018;59:1219\u201324.","journal-title":"J Nucl Med"},{"key":"969_CR113","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2967\/jnumed.122.264816","volume":"64","author":"K Shim","year":"2023","unstructured":"Shim K, Longtine MS, Abou DS, Hoegger MJ, Laforest RS, Thorek DLJ, et al. Cure of disseminated human lymphoma with [(177)Lu]Lu-ofatumumab in a preclinical model. J Nucl Med. 2023;64:542\u20138.","journal-title":"J Nucl Med"},{"key":"969_CR114","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"969_CR115","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","volume":"22","author":"M Ilic","year":"2016","unstructured":"Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22:9694\u2013705.","journal-title":"World J Gastroenterol"},{"key":"969_CR116","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1756283X13478680","volume":"6","author":"PE Oberstein","year":"2013","unstructured":"Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321\u201337.","journal-title":"Therap Adv Gastroenterol"},{"key":"969_CR117","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","volume":"99","author":"D Fong","year":"2008","unstructured":"Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290\u20135.","journal-title":"Br J Cancer"},{"key":"969_CR118","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00259-022-05954-y","volume":"50","author":"C Li","year":"2022","unstructured":"Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, et al. Theranostic application of (64)Cu\/(177)Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022;50:168\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"969_CR119","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:5.","journal-title":"N Engl J Med"},{"key":"969_CR120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1073\/pnas.96.6.2811","volume":"96","author":"TL Moser","year":"1999","unstructured":"Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A. 1999;96:6.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"969_CR121","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1158\/0008-5472.CAN-06-1094","volume":"67","author":"SL Chi","year":"2007","unstructured":"Chi SL, Wahl ML, Mowery YM, Shan S, Mukhopadhyay S, Hilderbrand SC, et al. Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. Cancer Res. 2007;67:4716\u201324.","journal-title":"Cancer Res"},{"key":"969_CR122","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1073\/pnas.131067798","volume":"98","author":"TL Moser","year":"2001","unstructured":"Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, et al. Endothelial cell surface F1-FO ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A. 2001;98:6.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"969_CR123","volume":"20","author":"BN Park","year":"2019","unstructured":"Park BN, Kim GH, Ko SA, Shin GH, Lee SJ, An YS, et al. Zr-89 immuno-PET targeting ectopic ATP synthase enables in-vivo imaging of tumor angiogenesis. Int J Mol Sci. 2019;20:3928.","journal-title":"Int J Mol Sci"},{"key":"969_CR124","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/antib13030051","volume":"13","author":"BN Park","year":"2024","unstructured":"Park BN, An YS, Kim SM, Lee SJ, Park YJ, Yoon JK. (177) Lu anti-angiogenic radioimmunotherapy targeting ATP synthase in gastric cancer model. Antibodies (Basel). 2024;13:51.","journal-title":"Antibodies (Basel)"},{"key":"969_CR125","volume":"13","author":"BJB Nelson","year":"2020","unstructured":"Nelson BJB, Andersson JD, Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications. Pharmaceutics. 2020;13:49.","journal-title":"Pharmaceutics"},{"key":"969_CR126","volume":"14","author":"SW Ling","year":"2022","unstructured":"Ling SW, de Blois E, Hooijman E, van der Veldt A, Brabander T. Advances in (177) Lu-PSMA and (225)Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer. Pharmaceutics. 2022;14:2166.","journal-title":"Pharmaceutics"},{"key":"969_CR127","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795\u2013802.","journal-title":"J Nucl Med"},{"key":"969_CR128","doi-asserted-by":"crossref","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1343\u201373.","DOI":"10.1200\/JCO.2017.76.6394"},{"key":"969_CR129","volume":"353","author":"BWS Robinson","year":"2005","unstructured":"Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:13.","journal-title":"N Engl J Med"},{"key":"969_CR130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/cncr.22061","volume":"107","author":"P Yuan","year":"2006","unstructured":"Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006;107:563\u20139.","journal-title":"Cancer"},{"key":"969_CR131","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.4049\/jimmunol.1300448","volume":"190","author":"S Abe","year":"2013","unstructured":"Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, et al. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol. 2013;190:6239\u201349.","journal-title":"J Immunol"},{"key":"969_CR132","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/cas.13979","volume":"110","author":"H Sudo","year":"2019","unstructured":"Sudo H, Tsuji AB, Sugyo A, Saga T, Kaneko MK, Kato Y, et al. Therapeutic efficacy evaluation of radioimmunotherapy with (90) Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma. Cancer Sci. 2019;110:1653\u201364.","journal-title":"Cancer Sci"},{"key":"969_CR133","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102503","volume":"10","author":"H Sudo","year":"2021","unstructured":"Sudo H, Tsuji AB, Sugyo A, Kaneko MK, Kato Y, Nagatsu K, et al. Preclinical evaluation of podoplanin-targeted alpha-radioimmunotherapy with the novel antibody NZ-16 for malignant mesothelioma. Cells. 2021;10:2503.","journal-title":"Cells"},{"key":"969_CR134","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.clgc.2016.09.002","volume":"15","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ, et al. Correlation of PSMA-targeted (18)F-DCFPyL PET\/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer. Clin Genitourin Cancer. 2017;15:e65\u20138.","journal-title":"Clin Genitourin Cancer"},{"key":"969_CR135","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/RLU.0000000000001618","volume":"42","author":"S Usmani","year":"2017","unstructured":"Usmani S, Ahmed N, Marafi F, Rasheed R, Amanguno HG, Al Kandari F. Molecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CT. Clin Nucl Med. 2017;42:410\u20133.","journal-title":"Clin Nucl Med"},{"key":"969_CR136","volume":"3","author":"Y Su","year":"2018","unstructured":"Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, et al. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018;3:e121497.","journal-title":"JCI Insight"},{"key":"969_CR137","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-20-3310","volume":"27","author":"S Wang","year":"2021","unstructured":"Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, et al. Molecular imaging of prostate cancer targeting CD46 using immunoPET. Clin Cancer Res. 2021;27:1305\u201315.","journal-title":"Clin Cancer Res"},{"key":"969_CR138","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-22-3291","volume":"29","author":"AP Bidkar","year":"2023","unstructured":"Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, et al. Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res. 2023;29:1916\u201328.","journal-title":"Clin Cancer Res"},{"key":"969_CR139","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40264-018-0772-x","volume":"42","author":"RR Shah","year":"2019","unstructured":"Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 2019;42:181\u201398.","journal-title":"Drug Saf"},{"key":"969_CR140","volume":"13","author":"PL Chia","year":"2020","unstructured":"Chia PL, Parakh S, Tsao MS, Pham NA, Gan HK, Cao D, et al. Targeting and efficacy of novel mAb806-antibody-drug conjugates in malignant mesothelioma. Pharmaceuticals (Basel). 2020;13:289.","journal-title":"Pharmaceuticals (Basel)"},{"key":"969_CR141","first-page":"6","volume":"104","author":"AM Scott","year":"2007","unstructured":"Scott AM, Lee F-T, Tebbutt N, Herbertson R, Gill SS, Liu Z, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA. 2007;104:6.","journal-title":"Proc Natl Acad Sci USA"},{"key":"969_CR142","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2967\/jnumed.123.266894","volume":"65","author":"CW Wichmann","year":"2024","unstructured":"Wichmann CW, Morgan KA, Cao Z, Osellame LD, Guo N, Gan H, et al. Radiolabeling and preclinical evaluation of therapeutic efficacy of (225)Ac-ch806 in glioblastoma and colorectal cancer xenograft models. J Nucl Med. 2024;65:1456\u201362.","journal-title":"J Nucl Med"},{"key":"969_CR143","first-page":"635","volume":"108","author":"A Burges","year":"2011","unstructured":"Burges A, Schmalfeldt B. Ovarian cancer: diagnosis and treatment. Dtsch Arztebl Int. 2011;108:635\u201341.","journal-title":"Dtsch Arztebl Int"},{"key":"969_CR144","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jso.21288","volume":"99","author":"J Sehouli","year":"2009","unstructured":"Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424\u20137.","journal-title":"J Surg Oncol"},{"key":"969_CR145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","volume":"100","author":"JG Jurcic","year":"2002","unstructured":"Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:7.","journal-title":"Blood"},{"key":"969_CR146","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41596-023-00825-8","volume":"18","author":"D Bauer","year":"2023","unstructured":"Bauer D, Sarrett SM, Lewis JS, Zeglis BM. Click chemistry: a transformative technology in nuclear medicine. Nat Protoc. 2023;18:1659\u201368.","journal-title":"Nat Protoc"},{"key":"969_CR147","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/ja8053805","volume":"130","author":"ML Blackman","year":"2008","unstructured":"Blackman ML, Royzen M, Fox JM. Tetrazine Ligation: Fast bioconjugation Based on Inverse-Electron-Demand Diels\u2212Alder Reactivity. J Am Chem Soc. 2008;130:2.","journal-title":"J Am Chem Soc"},{"key":"969_CR148","doi-asserted-by":"crossref","first-page":"E4066","DOI":"10.1073\/pnas.1406619111","volume":"111","author":"P Radhakrishnan","year":"2014","unstructured":"Radhakrishnan P, Dabelsteen S, Madsen FB, Francavilla C, Kopp KL, Steentoft C, et al. Immature truncated O-glycophenotype of cancer directly induces oncogenic features. Proc Natl Acad Sci USA. 2014;111:E4066-75.","journal-title":"Proc Natl Acad Sci USA"},{"key":"969_CR149","doi-asserted-by":"crossref","first-page":"108976","DOI":"10.1016\/j.nucmedbio.2024.108976","volume":"140\u2013141","author":"KN Mack","year":"2025","unstructured":"Mack KN, Bauer D, Carter LM, Carrasco SE, Atmane MI, Viray TD, et al. Pretargeted alpha therapy in MUC16-positive high-grade serous ovarian cancer. Nucl Med Biol. 2025;140\u2013141:108976.","journal-title":"Nucl Med Biol"},{"key":"969_CR150","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2010-05-282327","volume":"116","author":"SI Park","year":"2010","unstructured":"Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010;116:4231\u20139.","journal-title":"Blood"},{"key":"969_CR151","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2967\/jnumed.122.263962","volume":"64","author":"GT Havlena","year":"2023","unstructured":"Havlena GT, Kapadia NS, Huang P, Song H, Engles J, Brechbiel M, et al. Cure of micrometastatic B-cell lymphoma in a SCID mouse model using (213)Bi-anti-CD20 monoclonal antibody. J Nucl Med. 2023;64:109\u201316.","journal-title":"J Nucl Med"},{"key":"969_CR152","first-page":"12","volume":"29","author":"RF Meredith","year":"2014","unstructured":"Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. Cancer Biother Radiopharm. 2014;29:12\u20137.","journal-title":"Cancer Biother Radiopharm"},{"key":"969_CR153","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","volume":"98\u201399","author":"N Heynickx","year":"2021","unstructured":"Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. Nucl Med Biol. 2021;98\u201399:30\u20139.","journal-title":"Nucl Med Biol"},{"key":"969_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02636-x","volume":"42","author":"J Li","year":"2023","unstructured":"Li J, Huang T, Hua J, Wang Q, Su Y, Chen P, et al. CD46 targeted (212)Pb alpha particle radioimmunotherapy for prostate cancer treatment. J Exp Clin Cancer Res. 2023;42:61.","journal-title":"J Exp Clin Cancer Res"},{"key":"969_CR155","doi-asserted-by":"crossref","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12:173\u201381.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"969_CR156","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2967\/jnumed.123.266388","volume":"65","author":"D Bauer","year":"2024","unstructured":"Bauer D, Carter LM, Atmane MI, De Gregorio R, Michel A, Kaminsky S. 212Pb-Pretargeted Theranostics for Pancreatic Cancer. J Nucl Med. 2024;65(1):109\u201316.","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-025-00969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13139-025-00969-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-025-00969-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:59:43Z","timestamp":1791626383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13139-025-00969-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s13139-025-00969-3","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chi Soo Kang declares that he has no conflict of interest.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}